Market revenue in 2023 | USD 190.8 million |
Market revenue in 2030 | USD 326.4 million |
Growth rate | 8% (CAGR from 2023 to 2030) |
Largest segment | Immunohistochemistry |
Fastest growing segment | Digital Pathology and Workflow |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Immunohistochemistry, In situ Hybridization, Primary & Special Staining, Digital Pathology and Workflow, Anatomic Pathology, Molecular Pathology |
Key market players worldwide | Roche Holding AG ADR, Abbott Laboratories, Thermo Fisher Scientific Inc, Siemens AG, Danaher Corp, BioMerieux SA, Qiagen NV, BD, Merck KGaA, GE Aerospace, Agilent Technologies Inc, Biogenex, Cell Signaling Technology, Bio SB, DiaGenic |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to tissue diagnostics market will help companies and investors design strategic landscapes.
Immunohistochemistry was the largest segment with a revenue share of 25.68% in 2023. Horizon Databook has segmented the Spain tissue diagnostics market based on immunohistochemistry, in situ hybridization, primary & special staining, digital pathology and workflow, anatomic pathology, molecular pathology covering the revenue growth of each sub-segment from 2018 to 2030.
Healthcare in Spain is decentralized into 17 autonomous zones and these zones are responsible for delivery and functioning of healthcare. Tissue diagnostics in Spain are witnessing a healthy growth owing to the launch of newer technologies and increasing presence of bigger pharmaceutical & biotechnological companies.
This is aided by favorable government regulations that are in line with European regulations. Government policies include introduction of newer technologies and reimbursement of these new technologies are boosting the chances of commercialization and thus helping the market growth.
For instance, government is testing reimbursement in hospitals for some personalized medicine tests such as HER2 & KRAS that are supported by pharmaceutical companies. Increasing research, adoption and awareness for precision and personalized medicine is expected to play a key role in market development & commercialization of newer diagnostic and sequencing technologies.
Horizon Databook provides a detailed overview of country-level data and insights on the Spain tissue diagnostics market , including forecasts for subscribers. This country databook contains high-level insights into Spain tissue diagnostics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account